Supplementary Table 1 Non-dysplastic Barrett's esophagus annual progression rates to esophageal adenocarcinoma

Ref.	Type (retrospective, Prospective, meta-analysis)	Mean or median follow up (yrs)	Number of ND-BE subjects (number of HGD and/or EAC)	Prevalent LGD/HGD (y/n, %)	Annual progression to EAC
Shaheen et al[18]	Meta-analysis	-	-	Unknown	0.50%
Montgomery et al[32]	Retrospective	3.2	44	N	0%
Conio et al[32]	Prospective	5.5	150	N	0.36%
Dulai et al[26]	Retrospective	5.1	441	N	0.09%
Sharma et al[26]	Retrospective	4.2	616	N	0.39%
Vieth et al[123]	Retrospective	7.0	748	N	0.60%
Chang et al[19]	Systematic Review	3.7	996	Y LGD 8% HGD 2%	0.63%
Lim et al[28]	Retrospective	11	321	N	0.37%
Thomas et al[20]	Meta-analysis	3.2	11387	Y LGD 13%	0.70%
Yousef et al[21]	Meta-analysis	-	-	Y LGD 15.7%	0.53%
Wani et al[22]	Meta-analysis	-	-	N	0.60%
Curvers et al[24]	Retrospective	4.4	92 (2)	N	0.49%[1]
de Jonge et al[29]	Retrospective (Population)	4.8	38075	N	0.39%

Study	Type	Years	N	Dysplasia	Rate
Sikkema *et al*[23]	Meta-analysis	4.4	14109	Y LGD 11% HGD 3%	0.63%
Bhat *et al*[30]	Retrospective (Population)	7.0	8522	N	0.10%
Hvid-Jensen *et al*[31]	Retrospective (Population)	5.2	10407	N	0.10%
Jung *et al*[124]	Retrospective (Population)	7.8	300	N	0.26%
Schouten *et al*[33]	Retrospective (Population)	6.0	493	N	0.30%
Wani *et al*[34]	Retrospective	5.5	1204	N	0.27%
Desai *et al*[35]	Meta-analysis	5.1	11434	N	0.33%
Gaddam *et al*[36]	Retrospective	5	1400	N	0.32%
Duits *et al*[37]	Retrospective	4.0	153 (4)	N	0.6%[1]
Pereira *et al*[38]	Retrospective	5	331	Y LGD 1%	0.09%
Visrodia *et al*[39]	Retrospective (Population)	4.8	147 (5)	N	0.71%[1]
Krishnamoorthi *et al*[40]	Retrospective	3.8	480	N	0.11%
Peters *et al*[41]	Retrospective (Population)	4.9	12728	N	0.47%

[1]Combined neoplastic progression rates (HGD & EAC). EAC: Esophageal Adenocarcinoma; HGD: High grade dysplasia; LGD: Low grade dysplasia; NDBE: Non-dysplastic Barrett's esophagus.

Supplementary Table 2 Annual progression rates of low grade dysplasia to esophageal adenocarcinoma

Ref.	Type (retrospective, Prospective, meta-analysis)	Median or mean follow up (yr)	Total LGD-BE population	Combined outcomes with HGD? (Y/N)	Annual progression to EAC
Skacel *et al*[125]	Retrospective	2.2	25	N	3.7%
Schnell *et al*[49]	Retrospective	7.3	748	N	0.18%
Conio *et al*[25]	Prospective	5.5	40	N	0.9%
Dulai *et al*[26]	Retrospective	3.3	134	N	0.46%
Sharma *et al*[27]	Retrospective	4.2	618	N	0.6%
Veith *et al*[123]	Retrospective	4.5	19	N	4.5%
Lim *et al*[28]	Retrospective	11.0	34	N	0.8%
Gatenby *et al*[126]	Retrospective	4.0	146	N	1.35%
Shaheen *et al*[18]	Prospective	1.0	22	N	0%
Wani *et al*[22]	Meta-analysis	4.6	1512	N	1.7%
Curvers *et al*[24]	Retrospective	3.1	19	N	3.3%
De Jonge *et al*[29]	Retrospective	4.8	4132	N	0.77%
Bhat *et al*[30]	Retrospective	7.1	323	N	0.92%
Hvid-Jensen *et al*[31]	Retrospective	5.2	621	N	0.51%
Jung *et al*[124]	Retrospective	7.8	78	N	0.24%
Montgomery	Retrospective	1.8	15	N	11.4%

et al[32]					
Schouten et al[33]	Retrospective	5.3	92	N	0.41%
Wani et al[47]	Retrospective	6.2	210	N	0.44%
Phoa et al[45]	Prospective	3.0	68	N	2.9%
Singh et al[127]	Meta-analysis	-	-	N	0.54%
Duits et al[37]	Retrospective	1.6	79	Y	9.1%[1]
Visroida et al[39]	Retrospective	4.8	27	Y	3.86%[1]
Krishna-Moorthi et al[40]	Retrospective	4.8	244	Y	1.2%[1]
Duits et al[44]	Retrospective	3.5	255	Y	5.04%[1]
Barret et al[46]	RCT	3.0	42	N	2.4% (over 3 yr)

[1]Combined neoplastic progression rates (HGD & EAC). EAC: Esophageal Adenocarcinoma; HGD: High grade dysplasia; LGD: Low grade dysplasia; NDBE: Non-dysplastic Barrett's esophagus.

Supplementary Table 3 Annual progression rates of high grade dysplasia to esophageal adenocarcinoma

Ref.	Type	Mixed dysplasia cohort (Y/N)	Mean follow up (yr)	Total HGD-BE population	Annual progression to EAC
Reid et al[51]	Retrospective	N	-	76	7.02%
Weston et al[50]	Retrospective	N	1.9	15	8.70%
Montgomery et al[32]	Retrospective	N	1.9	15	31.25%
Schnell et al[49]	Retrospective	N	7.3	75	5%
Overholt et al[52]	RCT	N	3.3	70	8.14%
Rastogi et al[128]	Meta-analysis	N	5.3^{1}	236	$6.58\%^{1}$
Shaheen et al[42]	RCT	N	1.0	12	19%
Wani et al[22]	Meta-analysis	N	4.0	236	6.6%

^{1}Weighted incidence. EAC: Esophageal Adenocarcinoma; HGD: High grade dysplasia.

Supplementary Table 4 Studies representing 30- and 90-d mortality rates in surgery

Ref.	Patient number	Patient population of HGD/T1a/T1b	30-d mortality	90-d mortality
Otaki et al[77]	68	T1b	2.9%	-
Newton et al[54]	782	HGD, T1a, T1b	-	5%
Schwameis et al[76]	32	T1b	3%	-
Schölvinck et al[78]	26	T1b	0%	0%
Lorenz et al[57]	168	T1a, T1b	3% 'in-hospital mortality'	
Pech et al[129]	38	T1a	-	2.6%
Zehetner et al[96]	61	HGD, T1a	0%	0%
Pennathur et al[59]	100	T1a, T1b	0%	0%
Prasad et al[75]	46	T1a	4% 'in-hospital mortality'	
Rice et al[97]	122	HGD, T1a, T1b	2.5% 'operative mortality'	

HGD: High grade dysplasia.